Targeting the Inflammatory Niche in MDS By Tasquinimod Restores Hematopoietic Support and Suppresses Immune-Checkpoint Expression <i>in Vitro</i>
Manja Wobus(Heidelberg University), Katja Sockel(Innsbruck Medical University), Christoph Röllig(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden), Ekaterina Balaian(University Hospital Carl Gustav Carus), Friedrich Stölzel(German Cancer Research Center), Marie Törngren(Active Biotech (Sweden)), Helena Eriksson(Active Biotech (Sweden)), Kristin Möbus(Technische Universität Dresden), Uwe Platzbecker(National Center for Tumor Diseases), Russell Towers(Technische Universität Dresden), Triantafyllos Chavakis(Technische Universität Dresden), Rebekka Wehner(Technische Universität Dresden), Ivonne Habermann(Technische Universität Dresden), Uta Oelschlaegel(University Hospital Carl Gustav Carus)
Cited by 2
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Defining trained immunity and its role in health and disease
|Nature reviews. Immunology|2020|2.5k
Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities
|Nature reviews. Immunology|2021|1.6k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k